RecruitingPhase 3NCT06490328

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Sponsor

Dongkook Pharmaceutical Co., Ltd.

Enrollment

154 participants

Start Date

May 30, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Prostate Cancer

Summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Eligibility

Sex: MALEMin Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called DKF-MA102 in men with prostate cancer. The study aims to evaluate how safe the drug is and how well it works as a treatment, particularly in men who still have active testosterone levels. **You may be eligible if...** - You are a male aged 19 or older with a confirmed prostate cancer diagnosis - Your testosterone level is above 150 ng/dL (meaning you have not had full hormone suppression) - Your overall health is adequate (ECOG 0–2) - Your expected survival is at least 1 year **You may NOT be eligible if...** - You have had prior treatment that would interfere with this drug - You have significant heart, liver, or kidney problems - You have active serious infections Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.